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magnetic resonance imaging, allow us to identify these risk groups with considerably greater 134 precision today than was possible at the time when the study was being considered by the 135 EMA. Our results show that men with localised, low-risk PC can be treated in a way that not 136 only preserves their genitourinary function but also results in a lower progression rate, greater 137 chance of being declared disease-free, and reduction in need for whole-gland radical therapy 138 in the form of surgery or radiotherapy.
139
Implications of all the available evidence 140 When this study was designed, our risk stratification methods at diagnosis were poor. The 141 correction that was applied to mitigate the consequences of this imprecision was to offer 142 radical therapy to nearly all men, irrespective of attributed risk. Today we attribute risk with 143 greater precision using risk calculators, biomarkers, and imaging. Our study adds 144 considerable weight to the argument that we need to move away from a one-size-fits-all 145 approach to treatment and gradually replace it with a more risk-stratified approach to care.
146
We have AS for men at very low risk. We have radical therapy and multimodality treatments 147 for men at high risk for whom the consequences of treatment are matched by benefit.
148
Between these two extremes, we now have VTP, an intervention that preserves prostate tissue 149 when it is both possible and practical to do so. Given the precision of today's risk 150 stratification, future research will need to explore both the patient preferences and the upper 151 threshold of risk (as defined by tumour grade, volume, location, multiplicity) that should 152 determine where the transition point exists where tissue preservation is likely to confer 153 diminishing returns and should be supplanted by whole-gland radical therapy. Focal therapy and AS are both tissue-preserving strategies. They share the goal of preserving
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165
prostate tissue and consequently function by delaying or avoiding radical whole-gland 166 treatment in men in whom it is safe to do so. 4 However, focal therapy differs from AS in that 167 it treats disease-by the process of selective tissue ablation-above a certain risk threshold 168 and monitors disease below that threshold, as the latter is deemed to be clinically 169 insignificant. A risk-stratified clinical pathway that offers men focal therapy in a manner 170 complementary to AS might result in two potential benefits: a reduction in the probability of 171 failure or crossover to radical therapy and an increase in the proportion of men eligible and 172 willing to undergo a tissue-preserving treatment.
173
Neither focal therapy nor AS has previously been assessed in a prospective, comparative 174 efficacy study. Both have been assessed only in single-centre series, 2, 5, 6 in which the 175 outcomes were dependent on the population studied, the diagnostic precision at baseline, the 176 intensity and manner of the reclassification tests, and the study duration. that may have posed an additional risk to men undergoing VTP procedure were excluded.
209
Criteria for subject removal from the study were occurrence of a serious adverse event (SAE)
210
if recommended by the investigator, subject withdrawal, or a major protocol violation.
212
The study was conducted in compliance with Good Clinical Practice and according to a 
Randomisation and masking
217
Investigators enrolled subjects and allocated them to the VTP and AS groups in a 1:1 ratio 218 using a web-based randomisation system generated by the sponsor and stratified by centre 219 using balanced blocks of varied size (2 or 4 subjects). Treatment was open-label (subjects 220 and investigational site staff were not blinded to study treatment), but primary efficacy 221 outcomes were evaluated in a blinded manner.
222
Procedures
223
AS was conducted according to best practice at the time of study design. 
Statistical analysis
294
The sample size was based on an expected rate of progression from low to moderate or higher 295 risk of ≥15% over 2 years in the AS group and 5% in the VTP group. Using these 296 assumptions, the sample size required was 400 subjects (200 subjects per group), and at least 297 40 events (subjects with progression of cancer) needed to be observed for the final analysis to 298 take place.
299
Statistical analyses were conducted using SAS version 9.3. All randomised subjects were 300 analysed for efficacy according to assigned treatment in an intention-to-treat analysis.
Treatment failure (progression) was analysed by survival analysis. Times to progression were 302 compared between the two treatment groups using the log-rank test and quantified using a covariance. Other safety data, including, AEs, were summarised descriptively.
316
The trial is registered at ClinicalTrials.gov (NCT01310894).
317
Role of the funding source
318
The study sponsor and funder, STEBA Biotech S.A., developed the protocol in consultation 319 with the study investigators and the European Medicines Agency (EMA). STEBA performed 320 data management and statistical analysis and provided medical writing support for this report.
321
AAzzouzi and ME had full access to all data in the study. The final decision to submit this 322 report for publication was made jointly by all the authors. The corresponding author (ME)
323
had the final responsibility to submit for publication.
RESULTS
325
Subjects were recruited from AS group (n=6) than in the VTP group (n=17) withdrew consent before study completion.
333
Although unwillingness to accept randomisation to either group was an exclusion criterion,
334
the sponsor anticipated that subjects randomised to AS might withdraw because they had 
338
Demographic and baseline disease characteristics were well balanced between the two groups 339 and fit the profile of low-risk PC patients ( parameters: total number of positive cores (0.9 vs 2.3; p<0·0001), total cancer core length 377 (2.6 vs 6.8 mm; p<0·0001), and maximum cancer core length (1.6 vs 3.4 mm; p<0·0001).
378
Moreover, VTP produced a stable reduction in PSA of about 3 ng/mL over the course of the 379 study.
380
The nine subjects randomised to VTP but who had no treatment-related procedure were 381 excluded from the safety analysis (Figure 1 ). 
439
Since this is the first comparative efficacy study of its type, it is important to consider the 440 methodological considerations that were inherent in its design and conduct. The first relates 441 to the population studied. By today's standards this population might be considered low risk.
442
However, whilst the study was in development and being discussed with the EMA, neither
443
AS nor focal therapy were accepted as standard care. The EMA agreed that we could 444 reasonably exclude very-low-risk patients. Therefore, lower and upper thresholds of risk
445
(defined by Gleason pattern and tumour burden) were set, below which and above which men were excluded. This low-risk group was the only one that could have been studied at the time.
447
Were the study designed today, given the changes to risk categorisation, it is likely that men be offered it. Men with locally advanced disease should be offered multimodality therapy.
507
However, men who have low-risk, localised disease can now choose, on the basis of the 508 evidence that our study has generated, how to approach tissue preservation.
509
More research is needed to address unanswered questions, the principal one being the long- interpretation and final draft of the report and approved submission for publication. , 11 0,14 SD = standard deviation; TNM = tumour, nodes, metastasis; VTP = vascular-targeted photodynamic therapy. a Some of the subjects included on the basis of two biopsies at the beginning of the study had one of those two biopsies negative. 
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